A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye
Largely funded by government grants for the better part of its first decade, a UC Berkeley spinout has secured a new CEO and the funds to take its research into the clinic in early 2024.
The biotech, named by one of the co-founder’s daughters and originally scrapped together with NIH funds in the aftermath of the 2008-09 financial crisis, is also on a mission to upend the treatment of wet age-related macular degeneration, or AMD, with an injectable drug that it claims could be more durable than the “800-pound gorilla” in the room, Genentech’s Lucentis and Regeneron/Bayer’s Eylea.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
